18,558 Shares in scPharmaceuticals Inc. (NASDAQ:SCPH) Purchased by SG Americas Securities LLC

SG Americas Securities LLC bought a new position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 18,558 shares of the company’s stock, valued at approximately $66,000.

A number of other hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after acquiring an additional 3,101 shares during the period. Captrust Financial Advisors grew its holdings in scPharmaceuticals by 32.2% during the third quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock worth $85,000 after acquiring an additional 4,513 shares during the period. MetLife Investment Management LLC grew its holdings in scPharmaceuticals by 135.0% during the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock worth $77,000 after acquiring an additional 9,752 shares during the period. Virtu Financial LLC acquired a new position in scPharmaceuticals during the third quarter worth about $46,000. Finally, The Manufacturers Life Insurance Company acquired a new position in scPharmaceuticals during the third quarter worth about $57,000. 89.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on SCPH shares. Craig Hallum lowered their target price on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a research report on Thursday, November 14th.

scPharmaceuticals Trading Up 6.7 %

NASDAQ:SCPH opened at $3.68 on Friday. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a 1-year low of $3.08 and a 1-year high of $6.54. The firm has a market capitalization of $184.15 million, a price-to-earnings ratio of -1.94 and a beta of 0.11. The stock has a fifty day simple moving average of $3.38 and a 200 day simple moving average of $4.09.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.